Harrow Partners with Asembia to Improve Patient Access to Eyecare Medications

Harrow Enhances Patient Access to Eyecare Medications Through Strategic Collaboration

Harrow, a leading North American eyecare pharmaceutical company, has launched a groundbreaking digital patient access solution in partnership with Asembia, a prominent provider of specialty pharmacy and patient support services. This exclusive multi-year collaboration seeks to improve access to Harrow's diverse range of ophthalmic branded products, which includes well-known medications such as FLAREX®, ILEVRO®, and VIGAMOX®. By streamlining the prescribing process for eyecare professionals, the initiative aims to enhance the accessibility and affordability of these essential treatments for patients across the country.

The partnership relies heavily on Asembia’s non-dispensing pharmacy, ASPN Pharmacies, which employs advanced technology to facilitate collaboration among prescribers, patients, and payers. This approach ensures swift delivery of medications through patients' preferred pharmacies, which is critical for those who often face barriers when accessing care. Mark L. Baum, Harrow's CEO, underscores that this collaboration is designed to eliminate hurdles related to cost and access, enabling patients to embark on their prescription therapies more quickly and manage their refills with greater ease. The solution encompasses the entire patient journey, from prescription intake and benefits verification to prior authorization and co-pay support, thereby providing a comprehensive framework to enhance patient experience.

Harrow's partnership with Asembia represents a significant advancement in the delivery of eyecare medications, particularly for patients who have previously encountered challenges in accessing necessary treatments. The ASPN provider portal streamlines the ordering process for healthcare providers, allowing them to conveniently order multiple Harrow products in one go. This feature not only simplifies the logistical aspects of prescribing but also contributes to better health outcomes by promoting patient compliance. Lawrence Irene, CEO of Asembia, expresses enthusiasm for integrating Harrow’s high-quality products into their offerings, reinforcing the potential of this collaboration to improve treatment accessibility, especially for patients with limited options.

In addition to enhancing patient access, this partnership also emphasizes the importance of technology in modern healthcare. By leveraging advanced digital solutions, both companies aim to create a more efficient system that reduces administrative burdens and promotes timely care delivery. As the eyecare landscape continues to evolve, collaborations like this one are critical in addressing the ongoing challenges faced by patients and providers alike.

Overall, Harrow's innovative approach, combined with Asembia's expertise in specialty pharmacy services, marks a significant step forward in the eyecare pharmaceutical industry. This partnership not only aims to meet the immediate needs of patients but also sets a precedent for future collaborations that prioritize accessibility and affordability in healthcare.